SiSaf Ltd
John Stanton is an accomplished executive with extensive experience in leadership roles across various industries. Currently serving as Chief Executive Officer at Immortal Skin and Compact Imaging/Ocutell, Stanton has spearheaded initiatives in skin longevity research and innovative home-based imaging technology for AMD and DR patients. As a General Partner and Co-founder of SVG Ventures, Stanton focuses on seed and early-stage investments while also supporting startups through a dedicated accelerator program. Stanton holds significant roles at SiSaf Ltd as an investor, board member, and advisor, contributing to advancements in precision medicine and gene therapy. Previously, Stanton founded and led CubeGuard, held key positions at Palm and Handspring, and was a founding partner of the Eclipse Group, showcasing a strong background in technology, product management, and supply chain consulting, including noteworthy experience at Apple Computer.
This person is not in any teams
This person is not in any offices
SiSaf Ltd
SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.The company’s Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improvethe stability, safety, and transfection efficiency of RNA. SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through research partnerships.Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.